DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pulmonary Hypertension in Trisomy 21 Patients

Information source: Children's Healthcare of Atlanta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Congenital Disorders

Phase: N/A

Status: Completed

Sponsored by: Children's Healthcare of Atlanta

Official(s) and/or principal investigator(s):
Heather M Phelps, DO, Principal Investigator, Affiliation: Children's Healthcare of Atlanta

Summary

Evidence has shown poor outcome for adult patients with pre-operative pulmonary hypertension following closure of an atrial septal defect. Life-threatening pulmonary hypertensive crises may occur in these patients when they no longer have an atrial communication to decompress high right heart pressures. This concern has led some to advocate fenestrated patch closure of ASDs in patients with pulmonary hypertension with the prospect of a repeated procedure in order to close the fenestrations at a later date.

Clinical Details

Official title: Case Report: Resolution of Pulmonary Hypertension With Sildenafil and Bosentan in Patients With Trisomy 21 and Atrial Septal Defect

Study design: Time Perspective: Retrospective

Detailed description: Pre-operative resolution of pulmonary hypertension would clearly provide the best long-term outcome for these patients, allowing a definitive surgical procedure. There are no reported cases of resolution of pulmonary hypertension with the use of pulmonary vasodilators allowing successful ASD closure. We report the case of a patient with trisomy 21 and a primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life. Elevated pulmonary pressures were documented by cardiac catheterization during which the patient was found to have minimally responsive pulmonary vasculature to the administration of oxygen. He was started on pulmonary vasodilators which were continued for the following 5 months which resulted in gradual reduction in estimated PA pressure allowing successful closure of the primum ASD and repair of the cleft mitral valve. Following surgery, he was not restarted on pulmonary vasodilators and has continued to do well. The ability to reverse his pulmonary hypertension through the use of pulmonary vasodilators made him a candidate for his successful, definitive surgical repair. He currently has no residual cardiac problems and requires no cardiac medications. There will be no patient follow-up.

Eligibility

Minimum age: N/A. Maximum age: 8 Days. Gender(s): Both.

Criteria:

Inclusion Criteria:

- case report of a patient with trisomy 21 and primum atrial septum defect with

associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life Exclusion Criteria:

- those who do not fit into inclusion criteria

Locations and Contacts

Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States
Additional Information

Starting date: October 2004
Last updated: March 14, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017